We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BEYFORTUS (Sanofi-Aventis Australia Pty Ltd)
Product name
BEYFORTUS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
nirsevimab
Registration type
NCE/NBE
Indication
BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:
- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
BEYFORTUS should be used in accordance with official recommendations.